VaxEquity Strategic Collaboration with AstraZeneca

“The team at Scius provided us with excellent strategic advice around this important announcement with AstraZeneca. They were very responsive, working out of hours to ensure everything got done and in order to secure the best possible coverage. We were delighted by the extensive amount of coverage that has helped to put us on the map as a global leader in developing our self-amplifying RNA platform.”

Dr Mike Watson, Executive Chairman of VaxEquity

Objectives

Announce strategic collaboration with AstraZeneca to discover, develop and commercialise VaxEquity’s self-amplifying RNA platform.
Position VaxEquity as a pioneer and global leader in self-amplifying RNA.
Highlight the experience of its world class leadership team.

Strategy

Closely co-ordinating with key stakeholders including AstraZeneca and Imperial College London on press releases, key messages, QA and media briefings
Pre-briefed target journalists under embargo and set up one-on-one briefings under embargo, with further media follow up on day of release

Results

Extensive top tier global National coverage (Financial Times, Bloomberg, Reuters, Guardian and The Telegraph), as well as trade press (BioCentury, BioWorld, Endpoints, In Vivo, Fierce and Scrip)